The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ati-spg.com

Total Raised

$98.62M

Investors Count

10

Deal Terms

3

Autonomic Technologies Funding, Autonomic Technologies Valuation & Autonomic Technologies Revenue

6 Fundings

Autonomic Technologies's latest funding round was a Acquired for on January 1, 2020.

Autonomic Technologies's valuation in May 2009 was $63.13M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/1/2020

Acquired

0

FY undefined

1

6/25/2015

Series D - II

$99M

0

FY undefined

10

5/12/2015

Series D

$99M

0

FY undefined

10

10/7/2011

Series C

$99M

0

FY undefined

0

5/14/2009

Series B

$99M

$63.13M

0

FY undefined

0

Date

1/1/2020

6/25/2015

5/12/2015

10/7/2011

5/14/2009

Round

Acquired

Series D - II

Series D

Series C

Series B

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$63.13M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

0

0

Autonomic Technologies Deal Terms

3 Deal Terms

Autonomic Technologies's deal structure is available for 3 funding rounds, including their Series D from May 12, 2015.

Round

Series D

Series B

Series A

Funding Date

$99M

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

Dividend Rate

$99M

$99M

Liquidation Preferences

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

General Voting

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Autonomic Technologies Investors

10 Investors

Autonomic Technologies has 10 investors. Realeve invested in Autonomic Technologies's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/1/2020

1/1/2020

1
Acquired

Corporation

California

6/25/2015

6/25/2015

1
Series D - II

Venture Capital

Switzerland

5/14/2009

5/12/2015

3
Series B, Series C (2011), Series D (2015)

Venture Capital

California

00/00/0000

00/00/0000

Kleiner Perkins Caufield & Byers

Subscribe to see more

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Novartis Venture Funds

Subscribe to see more

Corporate Venture

Switzerland

First funding

1/1/2020

6/25/2015

5/14/2009

00/00/0000

00/00/0000

Last Funding

1/1/2020

6/25/2015

5/12/2015

00/00/0000

00/00/0000

Investor

Kleiner Perkins Caufield & Byers

Novartis Venture Funds

Rounds

1
Acquired
1
Series D - II
3
Series B, Series C (2011), Series D (2015)

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Type

Corporation

Venture Capital

Venture Capital

Venture Capital

Corporate Venture

Location

California

Switzerland

California

California

Switzerland

You May Also Like

A
Apneon

Apneon is an early stage medical device company developing devices for the treatment of sleep apnea.

L
LinguaFlex

Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.

N
Neuromonics

Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.

A
AllTranz

AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.

M
Monterey Devices

Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.

B
Beta-O2 Technologies

Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.